Development of small-molecule inhibitors of nonmuscle myosin II as chemical tools and antimetastatic therapeutics (CONFIDENTIAL)

01 October 2013 → 30 September 2017
Regional and community funding: Special Research Fund
Research disciplines
  • Natural sciences
    • Organic chemistry
  • Medical and health sciences
    • Morphological sciences
    • Oncology
    • Morphological sciences
    • Oncology
    • Biomarker discovery and evaluation
    • Drug discovery and development
    • Medicinal products
    • Pharmaceutics
    • Pharmacognosy and phytochemistry
    • Pharmacology
    • Pharmacotherapy
    • Toxicology and toxinology
    • Other pharmaceutical sciences
    • Morphological sciences
    • Oncology
synthesis Invasion cancer drug design myosin medicinal chemistry
Project description

The present proposal envisages the development of potent, isoform-selective small-molecule nonmuscle myosin II-inhibitors, based on the ‘confirmed hit’ blebbistatin. Such molecules have the potential to become highly valuable tools in the study of cell motility and malignant disease, and serve as leads for targeted anti-invasive pharmacotherapeutics with lowered resistance susceptibility.